Insight

PEI magazine A-Z of healthcare keynote interview

The pandemic has accelerated demand from diagnostics to mental healthcare, creating a red-hot deal market around ancillary care services.

Kristin C. Pothier

Kristin C. Pothier

Global and National Healthcare and Life Sciences Strategy Leader, and Global Deal Advisory Leader, Healthcare and Life Sciences, KPMG LLP

+1 617 549 2779

Glenn Mincey

Glenn Mincey

National Sector Leader, Private Equity, KPMG US

+1 212-954-8255

In an interview with Private Equity International Magazine, Glenn Mincey – National Sector Leader of Private Equity, and Kristin Pothier – Global Healthcare and Life Sciences Strategy Leader at KPMG, discuss the hyper active deal market around ancillary care services and the impact of COVID-19 on this space.

Key interview takeaways:

  • The variety of opportunities within ancillary care, as well as the its continued, essential position within the ecosystem of healthcare, make it attractive for private equity.
  • Ancillary care is being fueled by technological innovation, both due to COVID, and what will be a new horizon post COVID. Private equity will flow in to help fund this technology.
  • While COVID certainly put diagnostics center stage, therapeutic drugs of various sorts will be required more than ever as precision medicine continues its journey, providing on-going opportunity for investment and innovation far beyond COVID.
  • Intense deal competition will not let up and valuations will remain high once out to bid.
The trend of increasing PE investment into these businesses is likely to continue
— Glenn Mincey, National Sector Leader of Private Equity
There has been intense competition from almost every single asset that we have come across
— Kristin Pothier, Global Healthcare and Life Sciences Strategy Leader

Contact us

Glenn Mincey

Glenn Mincey

National Sector Leader, Private Equity, KPMG US

Kristin C. Pothier

Kristin C. Pothier

Global and National Healthcare and Life Sciences Strategy Leader, and Global Deal Advisory Leader, Healthcare and Life Sciences, KPMG LLP